NYSE$EW

Edwards Lifesciences Corp · Q1 2021 earnings

Q1 2021 earnings · · Investor relations

Briefing

Edwards Lifesciences reported first quarter results with sales growth and EPS exceeding expectations.

Edwards Lifesciences reported sales of $1.2 billion, an 8% increase over the prior year, with underlying sales growing by 5%. EPS reached $0.54, surpassing expectations. The company is confident in its 2021 outlook and raised its adjusted EPS guidance.

  • Sales grew 8 percent to $1.2 billion; underlying sales grew 5 percent
  • TAVR sales grew 7 percent; underlying sales grew 4 percent
  • EPS of $0.54 exceeded expectations
  • Adjusted EPS guidance of $2.07 to $2.27 increased $0.07

Headline financials

Total Revenue

$1.22B

Previous: $1.13B+7.8%
EPS (adj)

$0.54

Previous: $0.50+8.0%
Gross Profit Margin

75.9%

Previous: 76.5%-0.8%
SG&A Expenses

331000000.0%

Previous: 308000000.0%+7.5%
R&D Expenses

207000000.0%

Previous: 187000000.0%+10.7%
Capital Expenditures

-$106M

Previous: -$82.2M-29.0%
Free Cash Flow

$232M

Previous: $228M+1.7%
Net Income

$338M

Previous: $311M+8.9%
Operating Income

$384M

Previous: $358M+7.1%
Gross Profit

$923M

Previous: $864M+6.9%
Cash & Equivalents

$1.17B

Previous: $663M+77.1%
Total Assets

$7.21B

Previous: $6.08B+18.7%
Stock-Based Comp

$28.2M

Previous: $23.9M+18.0%

Revenue & EPS history

Edwards Lifesciences · Revenue · Quarterly

$1.22B

Q1 2021+7.8%vs Q1 2020
Beat estimate in 12 of 16 quarters(75%)
ActualEstimate

Revenue by segment

Edwards Lifesciences · $1.02B total across 3 segments · Q1 2021

  • Transcatheter Aortic Valve Replacement
    $792M+6.7%
  • Surgical Structural Heart
    $213M+10.1%
  • Transcatheter Mitral & Tricuspid
    $16M+52.4%

Forward guidance

Edwards Lifesciences anticipates total sales between $1.25 and $1.33 billion for the second quarter of 2021, with adjusted EPS projected to be $0.54 to $0.60. Full year 2021 sales guidance remains at $4.9 to $5.3 billion, and adjusted earnings per share are raised to $2.07 to $2.27.

Tailwinds

  • Full year 2021 sales guidance for Edwards remains at $4.9 to $5.3 billion.
  • Company is raising full year 2021 adjusted earnings per share to $2.07 to $2.27 from $2.00 to $2.20.
  • Company projects total sales to be between $1.25 and $1.33 billion for the second quarter of 2021.
  • Adjusted EPS of $0.54 to $0.60 for the second quarter of 2021.
  • Confident in long-term patient-focused strategy and innovation pipeline.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2021

Historical avgQ1 2021

-1.3%

Avg return

Earnings day

-2.1%

Avg return

5 days after

-1.5%

Avg return

30 days after

50%

35 / 70 earnings

Positive

+11.6%

Q1 2017

Best reaction

-31.4%

Q2 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-1.1%+1.9%+7.7%
Q4 2025+3.0%-1.5%+6.2%
Q3 2025-0.8%-0.8%+3.8%
Q2 2025+0.1%+4.1%-0.8%
Q1 2025+6.6%+8.3%+6.4%
Q4 2024+6.9%+7.4%-2.3%
Q3 2024-1.7%-1.8%-0.2%
Q2 2024-31.4%-26.8%-18.6%
Q1 2024-2.5%-4.4%-0.7%
Q4 2023+0.6%-1.2%+9.0%
Q3 2023-10.9%-11.5%-3.7%
Q2 2023-9.8%-10.5%-16.9%
Q1 2023-1.2%-0.3%-6.6%
Q4 2022+7.1%+8.0%+5.5%
Q3 2022-18.3%-16.3%-12.0%
Q2 2022-4.8%-3.2%-13.6%
Q1 2022-8.3%-11.7%-17.7%
Q4 2021-6.9%-0.3%+3.2%
Q3 2021-0.4%-1.2%-6.4%
Q2 2021+2.0%+4.2%+5.8%
Q1 2021+7.5%+10.0%+4.8%
Q4 2020-3.7%-5.3%-4.0%
Q3 2020-6.0%-7.5%+0.1%
Q2 2020+0.3%-0.6%+1.0%
Q1 2020+3.2%-1.6%+1.1%
Q4 2019-5.5%-2.7%-12.0%
Q3 2019+3.0%+6.8%+8.4%
Q2 2019+10.8%+9.7%+11.7%
Q1 2019-0.3%-1.2%-4.7%
Q4 2018-0.0%+0.8%+2.9%
Q3 2018-6.0%-6.1%-0.7%
Q2 2018-8.5%-8.2%-8.6%
Q1 2018-5.6%-5.8%+0.3%
Q4 2017+4.1%+0.4%+6.3%
Q3 2017-9.4%-10.7%-4.6%
Q2 2017+0.4%-0.6%-3.5%
Q1 2017+11.6%+12.0%+16.5%
Q4 2016-6.8%-6.6%-3.9%
Q3 2016-19.5%-17.8%-25.8%
Q2 2016+7.4%+7.5%+7.7%
Q1 2016+0.9%
Q4 2015+5.7%
Q3 2015+0.7%
Q2 2015+0.7%
Q1 2015-1.8%
Q4 2014+7.5%
Q3 2014+10.9%
Q2 2014+9.4%
Q1 2014+0.7%
Q4 2013+1.0%
Q3 2013-9.3%
Q2 2013+2.3%
Q1 2013-22.8%
Q4 2012-7.1%
Q3 2012-0.3%
Q2 2012+4.5%
Q4 2011-1.6%
Q1 2012+11.6%
Q3 2011-5.9%
Q2 2011-3.5%
Q4 2010+0.5%
Q1 2010+0.5%
Q1 2011-2.1%
Q4 2008-1.7%
Q1 2009-1.7%
Q3 2010+1.3%
Q3 2009+1.3%
Q2 2009+1.3%
Q2 2010+1.3%
Q4 2009+1.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro